Company: CNTB
Filing Date: 2025-06-10
Form Type: F-3
Source: 0001193125-25-138482
Chunk: 15

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-06-10
Form: F-3
Chunk 15
---
 on our business, financial condition and results of operations. |

Risks Related to Intellectual Property

| • |     | Our success depends on our ability to obtain, maintain, protect and enforce our intellectual property and our 
 proprietary technologies.                                                                                     |

9

| • |     | If we fail to comply with our obligations under any license, collaboration or other agreements, or otherwise                                                                                                                                           
 experience disruptions to our business relationships with our collaborators or future licensors, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our current and future 
 Product Candidates.                                                                                                                                                                                                                                    |

| • |     | If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent                                                                   
 protection, our ability to prevent our competitors and other third parties from commercializing Product Candidates similar or identical to ours would be adversely affected. |

| • |     | The patent protection and patent prosecution for our current or any future Product Candidates may be dependent 
 on third parties.                                                                                              |

| • |     | If we are not successful in obtaining patent term extensions for our current and future Product Candidates,                                                                                                                                       
 our business may be harmed, and the lack of effective enforcement of patent linkage and the absence of patent term extension and data and market exclusivity for Product Candidates approved by the NMPA could increase the risk of early generic 
 competition with our products in the PRC.                                                                                                                                                                                                         |

| • |     | Obtaining and maintaining our patent protection depends on compliance with various procedural, document                                                                                     
 submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements. |

| • |     | Third-party claims or litigation alleging infringement, misappropriation or other violation of, or seeking to                                                                    
 invalidate, patents or other intellectual and proprietary rights, may delay or prevent the development and commercialization of any of our current or future Product Candidates. |

| • |     | We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or                      
 expiration of a third-party patent, which might adversely affect our ability to develop and market our Product Candidates. |

| • |     | We may need to acquire or license intellectual property from third parties, and such licenses may not be 
 available or may not be available on commercially reasonable terms.                                      |

| • |     | We may become involved in lawsuits to protect or enforce our patents or other intellectual property rights, 
 which could